SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for ClearPoint Neuro, Inc. (CLPT) (CIK 0001285550) (CLPT) — Jul 6, 2012

ClearPoint Neuro, Inc. (CLPT) (CIK 0001285550)
Date: July 6, 2012 · CIK: 0001285550 · Accession: 0000000000-12-035456

Financial Reporting Regulatory Compliance Internal Controls

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 000-54575

Date
July 6, 2012
Author
/s/ Amanda Ravitz
Form
UPLOAD
Company
ClearPoint Neuro, Inc. (CLPT) (CIK 0001285550)

Letter

July 6, 2012 Via E -mail Kimble L. Jenkins Chief Executive Officer MRI Interventions, Inc. One Commerce Square, Suite 2550 Memphis, TN 38103

Re: MRI Interventions, Inc. Form 10 Filed December 28 , 2012 File No. 000-54575

Dear Mr. Jenkins :

We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Amanda Ravitz

Show Raw Text
July 6, 2012

Via E -mail
Kimble L. Jenkins
Chief Executive Officer
MRI Interventions, Inc.
One Commerce Square, Suite 2550
Memphis, TN 38103

Re: MRI Interventions, Inc.
Form 10
Filed December 28 , 2012
File No. 000-54575

Dear Mr. Jenkins :

We have completed our review of your filing .  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Amanda Ravitz

Amanda Ravitz
Assistant Director

cc: Robert J . DelPriore, Esq.
 Baker, Donelson, Bearman, Caldwell & Berkowitz, PC